Researchers proposed a tissue engineering strategy using uterine endometrium-derived mesenchymal stem/stromal cells (eMSC) delivered with degradable poly L-lactic acid-co-poly ε-caprolactone (PLACL) and evaluated the immunomodulatory mechanism at the material interfaces.
[Biomaterials Advances]